KR102766089B1 - 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료 - Google Patents

오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료 Download PDF

Info

Publication number
KR102766089B1
KR102766089B1 KR1020207014191A KR20207014191A KR102766089B1 KR 102766089 B1 KR102766089 B1 KR 102766089B1 KR 1020207014191 A KR1020207014191 A KR 1020207014191A KR 20207014191 A KR20207014191 A KR 20207014191A KR 102766089 B1 KR102766089 B1 KR 102766089B1
Authority
KR
South Korea
Prior art keywords
obinutuzumab
cycle
pharmaceutical composition
administration
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207014191A
Other languages
English (en)
Korean (ko)
Other versions
KR20200067196A (ko
Inventor
미하엘 벵거
메르다드 모바셔
친-유 린
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102766089(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Priority to KR1020247035575A priority Critical patent/KR102906969B1/ko
Publication of KR20200067196A publication Critical patent/KR20200067196A/ko
Application granted granted Critical
Publication of KR102766089B1 publication Critical patent/KR102766089B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020207014191A 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료 Active KR102766089B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247035575A KR102906969B1 (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
US62/574,297 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247035575A Division KR102906969B1 (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Publications (2)

Publication Number Publication Date
KR20200067196A KR20200067196A (ko) 2020-06-11
KR102766089B1 true KR102766089B1 (ko) 2025-02-13

Family

ID=64362606

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207014191A Active KR102766089B1 (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료
KR1020247035575A Active KR102906969B1 (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료
KR1020257043253A Pending KR20260011191A (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247035575A Active KR102906969B1 (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료
KR1020257043253A Pending KR20260011191A (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Country Status (14)

Country Link
US (2) US12129304B2 (https=)
EP (2) EP3697818B1 (https=)
JP (2) JP6860652B2 (https=)
KR (3) KR102766089B1 (https=)
CN (2) CN120983618A (https=)
AU (2) AU2018303836B2 (https=)
BR (1) BR112020007731A2 (https=)
CA (1) CA3079374A1 (https=)
ES (1) ES3005784T3 (https=)
IL (2) IL321935A (https=)
MX (2) MX419643B (https=)
PL (1) PL3697818T3 (https=)
TW (2) TWI828593B (https=)
WO (1) WO2019017499A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102766089B1 (ko) * 2017-10-19 2025-02-13 에프. 호프만-라 로슈 아게 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료
US20240050562A1 (en) * 2019-10-04 2024-02-15 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
JP7802811B2 (ja) 2021-09-17 2026-01-20 キヤノン株式会社 送電装置および受電装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
KR101247418B1 (ko) 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
US20170239351A1 (en) * 2014-08-11 2017-08-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
CN110945068A (zh) 2017-07-21 2020-03-31 横滨橡胶株式会社 充气轮胎
KR102766089B1 (ko) * 2017-10-19 2025-02-13 에프. 호프만-라 로슈 아게 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Adv Ther 34:324-356, (Published online: December 21, 2016)*

Also Published As

Publication number Publication date
EP3697818A2 (en) 2020-08-26
EP4520347A3 (en) 2025-06-04
KR20240157135A (ko) 2024-10-31
KR102906969B1 (ko) 2026-01-05
CN111212854A (zh) 2020-05-29
JP2019528282A (ja) 2019-10-10
US20200299398A1 (en) 2020-09-24
IL273909A (en) 2020-05-31
JP2021152002A (ja) 2021-09-30
US20250026847A1 (en) 2025-01-23
CA3079374A1 (en) 2019-01-24
US12129304B2 (en) 2024-10-29
WO2019017499A3 (en) 2019-02-21
MX419643B (es) 2025-01-14
AU2025205481A1 (en) 2025-08-07
TW201922284A (zh) 2019-06-16
KR20260011191A (ko) 2026-01-22
TWI828593B (zh) 2024-01-01
JP6860652B2 (ja) 2021-04-21
TW202342099A (zh) 2023-11-01
PL3697818T3 (pl) 2025-03-24
EP3697818B1 (en) 2024-11-27
JP7370357B2 (ja) 2023-10-27
KR20200067196A (ko) 2020-06-11
AU2018303836A1 (en) 2020-05-14
MX2020003418A (es) 2020-07-20
EP4520347A2 (en) 2025-03-12
IL321935A (en) 2025-09-01
CN120983618A (zh) 2025-11-21
IL273909B2 (en) 2025-12-01
MX2024009217A (es) 2024-11-08
BR112020007731A2 (pt) 2020-10-20
AU2018303836B2 (en) 2025-04-17
ES3005784T3 (en) 2025-03-17
WO2019017499A2 (en) 2019-01-24
TWI805630B (zh) 2023-06-21
IL273909B1 (en) 2025-08-01

Similar Documents

Publication Publication Date Title
IL273937B2 (en) Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
US20250026847A1 (en) Treatment of cd20-positive b-cell lymphoma with obinutuzumab
CN116134140B (zh) 长效作用的il-15及其用途
JP2025156294A (ja) 皮下投与のための抗ｃｄ３８抗体の製剤
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
Johnson Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
CN117769435A (zh) 通过施用抗cd127剂治疗cd127阳性癌症的方法
HK40031517A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
US20220119523A1 (en) Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
US12599620B2 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
BR122025025322A2 (pt) Composição farmacêutica para o tratamento de linfoma de células b e uso do obinutuzumabe

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601